-
公开(公告)号：US20170327488A1
公开(公告)日：2017-11-16
申请号：US15607326
申请日：2017-05-26
发明人： Erik Mogalian , Robert William Scott , Bing Shi , Fang Wang
IPC分类号： C07D403/14
CPC分类号： C07D403/14 , A61K31/381 , A61K31/4184 , A61K31/7056 , C07B2200/13 , C07D471/08 , C07D487/08
摘要： Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
-
公开(公告)号：US09682987B2
公开(公告)日：2017-06-20
申请号：US14825386
申请日：2015-08-13
发明人： Erik Mogalian , Robert William Scott , Bing Shi , Fang Wang
IPC分类号： C07D403/14 , C07D487/08 , A61K31/4184 , A61K31/7056 , A61K31/381 , C07D471/08
CPC分类号： C07D403/14 , A61K31/381 , A61K31/4184 , A61K31/7056 , C07B2200/13 , C07D471/08 , C07D487/08
摘要： Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
-
公开(公告)号：US20160340345A1
公开(公告)日：2016-11-24
申请号：US15228825
申请日：2016-08-04
发明人： Robert William Scott , Justin Philip Vitale , Kenneth Stanley Matthews , Martin Gerald Teresk , Alexandra Formella , Jared Wayne Evans
IPC分类号： C07D403/14
CPC分类号： C07D403/14 , C07D403/04 , Y02P20/55
摘要： The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.
摘要翻译： 其作为抗病毒剂是有用的。 本公开还提供了作为式I化合物的合成中间体的化合物。
-
公开(公告)号：US20150344488A1
公开(公告)日：2015-12-03
申请号：US14825386
申请日：2015-08-13
发明人： Erik Mogalian , Robert William Scott , Bing Shi , Fang Wang
IPC分类号： C07D487/08
CPC分类号： C07D403/14 , A61K31/381 , A61K31/4184 , A61K31/7056 , C07B2200/13 , C07D471/08 , C07D487/08
摘要： Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5 -(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro [2 .4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
摘要翻译： 抗HCV化合物（1- {3- [6-（9,9-二氟-7- {2- [5-（2-甲氧基羰基氨基-3-甲基 - 丁酰基）-5-氮杂）的无定形和结晶固体形式 - 螺[2.4]庚-6-基] -3H-咪唑-4-基} -9H-芴-2-基）-1H-苯并咪唑-2-基] -2-氮杂 - 双环[2.2.1 ]庚烷-2-羰基} -2-甲基 - 丙基） - 氨基甲酸甲酯（化合物I），并以固体状态表征：还提供了制备方法和使用无定形和结晶形式的方法。
-
公开(公告)号：US20150141659A1
公开(公告)日：2015-05-21
申请号：US14600911
申请日：2015-01-20
发明人： Erik Mogalian , Robert William Scott , Bing Shi , Fang Wang
IPC分类号： C07D403/14
CPC分类号： C07D403/14 , A61K31/381 , A61K31/4184 , A61K31/7056 , C07B2200/13 , C07D471/08 , C07D487/08
摘要： Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
摘要翻译： 抗HCV化合物（1- {3- [6-（9,9-二氟-7- {2- [5-（2-甲氧基羰基氨基-3-甲基 - 丁酰基）-5-氮杂的无定形和结晶固体形式 - 螺[2.4]庚-6-基] -3H-咪唑-4-基} -9H-芴-2-基）-1H-苯并咪唑-2-基] -2-氮杂 - 双环[2.2.1]庚烷 -2-羰基} -2-甲基 - 丙基） - 氨基甲酸甲酯（化合物I），并以固态表征：还提供了制备方法和使用无定形和结晶形式的方法。
-
公开(公告)号：US20150232453A1
公开(公告)日：2015-08-20
申请号：US14704627
申请日：2015-05-05
发明人： Robert William Scott , Justin Philip Vitale , Kenneth Stanley Matthews , Martin Gerald Teresk , Alexandra Formella , Jared Wayne Evans
IPC分类号： C07D403/04
CPC分类号： C07D403/04 , C07D403/14 , Y02P20/55
摘要： The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.
摘要翻译： 本公开提供了制备式I化合物的方法：其可用作抗病毒剂。 本公开还提供了作为式I化合物的合成中间体的化合物。
-
公开(公告)号：US09056860B2
公开(公告)日：2015-06-16
申请号：US13800202
申请日：2013-03-13
发明人： Robert William Scott , Justin Philip Vitale , Kenneth Stanley Matthews , Martin Gerald Teresk , Alexandra Formella , Jared Wayne Evans
IPC分类号： C07D403/14 , C07D403/04
CPC分类号： C07D403/14 , C07D403/04 , Y02P20/55
摘要： The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.
摘要翻译： 本公开提供了制备式I化合物的方法：其可用作抗病毒剂。 本公开还提供了作为式I化合物的合成中间体的化合物。
-
公开(公告)号：US08969588B2
公开(公告)日：2015-03-03
申请号：US13800374
申请日：2013-03-13
发明人： Robert William Scott , Fang Wang , Bing Shi , Erik Mogalian
IPC分类号： C07D403/14 , A61K31/4184 , A61K31/7056 , A61K31/381 , C07D471/08
CPC分类号： C07D403/14 , A61K31/381 , A61K31/4184 , A61K31/7056 , C07B2200/13 , C07D471/08 , C07D487/08
摘要： Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2 -[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl -propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
摘要翻译： 抗HCV化合物的无定形和结晶固体形式（1- {3- [6-（9,9-二氟-7- {2- [5-（2-甲氧基羰基氨基-3-甲基 - 丁酰基）-5-氮杂 - 螺[2.4]庚-6-基] -3H-咪唑-4-基} -9H-芴-2-基）-1H-苯并咪唑-2-基] -2-氮杂 - 双环[2.2.1]庚烷 -2-羰基} -2-甲基 - 丙基） - 氨基甲酸甲酯（化合物I），并以固态表征：还提供了制备方法和使用无定形和结晶形式的方法。
-
公开(公告)号：US09718807B2
公开(公告)日：2017-08-01
申请号：US15228825
申请日：2016-08-04
发明人： Robert William Scott , Justin Philip Vitale , Kenneth Stanley Matthews , Martin Gerald Teresk , Alexandra Formella , Jared Wayne Evans
IPC分类号： C07D403/14 , C07D403/04
CPC分类号： C07D403/14 , C07D403/04 , Y02P20/55
摘要： The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.
-
公开(公告)号：US09139570B2
公开(公告)日：2015-09-22
申请号：US14600911
申请日：2015-01-20
发明人： Erik Mogalian , Robert William Scott , Bing Shi , Fang Wang
IPC分类号： C07D403/14 , A61K31/4184 , A61K31/7056 , A61K31/381 , C07D471/08
CPC分类号： C07D403/14 , A61K31/381 , A61K31/4184 , A61K31/7056 , C07B2200/13 , C07D471/08 , C07D487/08
摘要： Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
摘要翻译： 抗HCV化合物（1- {3- [6-（9,9-二氟-7- {2- [5-（2-甲氧基羰基氨基-3-甲基 - 丁酰基）-5-氮杂的无定形和结晶固体形式 - 螺[2.4]庚-6-基] -3H-咪唑-4-基} -9H-芴-2-基）-1H-苯并咪唑-2-基] -2-氮杂 - 双环[2.2.1]庚烷 -2-羰基} -2-甲基 - 丙基） - 氨基甲酸甲酯（化合物I），并以固态表征：还提供了制备方法和使用无定形和结晶形式的方法。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.019 秒)
